Work

Case with Refractory Myasthenia Gravis Caused by Pembrolizumab

Year: 2025

Type: article

Abstract: Nowadays, checkpoint inhibitors play a major role in the management of different types of cancers. However, we have seen variants of immune therapy-related adverse events, which usually are variables from fatigue, to neuropathy to severe devastating complications such as respiratory failure due to myasthenia gravis (MG), as we saw in our case. Our patient was started on pembrolizumab, and they developed severe respiratory failure attributed to MG after three weeks from treatment initiation. Also, the patient presented with myositis, mild myocarditis and hepatitis, which were all related to pembrolizumab.

Source: Journal of Community Hospital Internal Medicine Perspectives

DOI: 10.55729/2000-9666.1486

Authors: Khaled M. Darwesh, Bushra Amer, Lateefah D. Hawshab, Fatima D Hawshab

Institutions: Berkshire Medical Center, Providence St. Peter Hospital

Language: English

Topic: Cancer Immunotherapy and Biomarkers

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $500